ATRC achieved a dramatic financial turnaround with revenue surging 304% to $201.6M and operating cash flow jumping 370% to $57.3M, while significantly narrowing losses.
This represents a transformative year for AtriClip with revenues quadrupling and the company moving much closer to profitability, suggesting strong market adoption of their cardiac surgery products. The substantial improvement in operating cash flow generation indicates the business model is scaling effectively and moving toward sustainability.
ATRC delivered exceptional financial performance with revenue growing 304% to $201.6M and operating cash flow surging 370% to $57.3M, demonstrating strong business momentum. Operating losses narrowed dramatically by 76% to -$9.4M despite higher interest expenses, while the company strengthened its balance sheet with cash increasing 36% to $167.4M and reduced capital expenditures by 21%. The overall picture signals a company experiencing rapid growth while moving decisively toward profitability, with improved operational efficiency and strong cash generation supporting the scaling business.
Operating cash flow surged 369.8% — exceptional cash generation, highest quality earnings signal.
Strong top-line growth of 303.7% — accelerating demand or successful expansion into new markets.
Operating leverage kicking in — revenue growth outpacing cost growth, a hallmark of scaling businesses.
Net income grew 74.4% — bottom-line growth signals improving overall business health.
Interest expense surged 38.9% — significant debt increase or rising rates materially impacting earnings.
Cash position surged 36.4% — strong cash generation or capital raise providing significant financial cushion.
Capex reduced 21% — investment cycle winding down or capital discipline; may improve near-term free cash flow.
Current assets grew 20.4% — improving short-term liquidity or inventory/receivables build.
Gross profit expanding — improving pricing power or product mix shift toward higher-margin offerings.
Current liabilities rose 11% — increased short-term obligations, watch current ratio.
See what changed in your portfolio's filings
500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.
Try Tracenotes free →